Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.38 |
| ▸ | GRM5 | P41594 | 5/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | PRKACG | P22612 | 1/20 | 0.34 |
| ▸ | PRKACB | P22694 | 1/20 | 0.34 |
| ▸ | GRK6 | P43250 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753084 | 0.89 | CYP19A1 (0.41) | TP53GRM5S1PR1MAPTRXFP1 | |
| SCHEMBL10182667 | 0.89 | S1PR1 (0.47) | TP53S1PR1MAPTHTTRXFP1 | |
| SCHEMBL10181574 | 0.83 | TP53 (0.47) | TP53GRM5MAPTNPC1PKM | |
| SCHEMBL3761562 | 0.80 | NPC1 (0.56) | TP53GRM5S1PR1MAPTNPC1 | |
| SCHEMBL3755993 | 0.79 | S1PR1 (0.52) | TP53S1PR1MAPTNPC1PKM | |
| SCHEMBL10181580 | 0.79 | S1PR1 (0.47) | TP53S1PR1MAPTRXFP1NPC1 | |
| SCHEMBL3764576 | 0.79 | RAB9A (0.49) | TP53GRM5S1PR1MAPTHTT | |
| SCHEMBL20405846 | 0.79 | TP53 (0.42) | TP53GRM5S1PR1MAPTRXFP1 | |
| SCHEMBL3762524 | 0.79 | S1PR1 (0.59) | TP53GRM5S1PR1MAPTRXFP1 | |
| SCHEMBL3755692 | 0.78 | S1PR1 (0.47) | TP53S1PR1MAPTRXFP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | OXA1L, RO60, PDCD11 | TP53 2220/4885GRM5 1824/4885S1PR1 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.